Fig 1: Microarray expression profile of genes associated with drug resistance differentiating between the ovarian cancer samples (groups A and B) from control samples (group C) (p<0.05) for: UBA2, ubiquitin-like modifier-activating enzyme 2; GLO1, glyoxalase I; STATH, statherin; TUFT1, tuftelin 1; RIC8A, RIC8 guanine nucleotide exchange factor B; ABCC5, ATP-binding cassette subfamily C member 5; HPD, 4-hydroxyphenylpyruvate dioxygenase; GBF1, Golgi brefeldin A-resistant guanine nucleotide exchange factor 1; (+), overexpression in comparison with the control (–);, downregulation in comparison with the control.
Fig 2: Changes in miRNA expression levels for differentiating ovarian cancer samples (groups A and B) from control samples (group C) that are potentially involved in regulating the expression of the selected transcripts, for UBA2, ubiquitin-like modifier-activating enzyme 2; GLO1, glyoxalase I; STATH, statherin, TUFT1, tuftelin 1; RIC8A, RIC8 guanine nucleotide exchange factor B; ABCC5, ATP-binding cassette subfamily C member 5; HPD, 4-hydroxyphenylpyruvate dioxygenase; GBF1, Golgi brefeldin A-resistant guanine nucleotide exchange factor 1. (+), overexpression in comparison with the control; (-), downregulation in comparison with the control.
Fig 3: miRNAs affecting the transcriptional activity of genes differentiating ovarian cancer samples compared to the control samples. UBA2, ubiquitin-like modifier-activating enzyme 2; GLO1, glyoxalase I; STATH, statherin, TUFT1, tuftelin 1; RIC8A, RIC8 guanine nucleotide exchange factor B; ABCC5, ATP-binding cassette subfamily C member 5; HPD, 4-hydroxyphenylpyruvate dioxygenase; GBF1, Golgi brefeldin A-resistant guanine nucleotide exchange factor 1.
Supplier Page from MyBioSource.com for Human SUMO-activating enzyme subunit 2, UBA2 ELISA Kit